Sansure Biotech

Sansure Biotech Inc. is an in-vitro diagnostics overall solution provider with independent innovative genetic technology at its core, integrating diagnostic reagents, instruments, and third-party medical laboratory services. It is listed on the Science and Technology Innovation Board (stock code: 688289), selected as a constituent stock of the "STAR 50" index, and listed among China's Top 100 Pharmaceutical Enterprises and Hunan Province's Top 100 Enterprises. The company is committed to becoming a popularizer of genetic technology, serving the construction of the national precision medicine system and the hierarchical diagnosis and treatment system. It is a National Demonstration Center for Gene Detection Technology Application, a National-Local Joint Engineering Research Center for Infectious Disease and Tumor Gene Diagnosis Technology, a National Technological Innovation Demonstration Enterprise, a Post-Doctoral Scientific Research Workstation, and a National Intellectual Property Demonstration Enterprise. Headquartered in Changsha, the company has built an international key hub in Shanghai, and has established subsidiaries or branches in major cities across China such as Beijing and Chengdu, as well as in global regions including the United Kingdom, France, Indonesia, and the Philippines. The company has built an international talent team, gathering more than 10 national and provincial industry leading talents and over 100 high-level returned overseas students. Adhering to the mission of providing affordable and user-friendly genetic technologies, products, and services to people worldwide, and focusing on promoting the "Five Modernizations" of genetic technology—making it more precise, simplified, automated, mobile, and systematic—the company has independently developed a series of core technologies, including high-precision "magnetic bead method," rapid and simple "one-step method," universal "fully automated unified sample processing," and "POCT mobile molecular diagnostics." It has built a series of molecular diagnostic technology platforms such as fluorescence quantitative PCR, gene chips, gene sequencing, mobile molecular diagnostics, and bioinformatics. The company has won more than 50 major awards including the National Science and Technology Progress Second Prize and the China Patent Award, and has undertaken more than 50 national and provincial key projects such as national "12th Five-Year" and "13th Five-Year" major science and technology special projects. It is gradually building a new ecosystem for the universal and full-scenario application of genetic technology, filling multiple gaps in the domestic industry, leading domestic industry technology to catch up with and surpass international advanced levels, effectively breaking import monopoly, and promoting the transformation of genetic technology from application in individual departments of medical institutions to multi-department application, from application in high-end laboratories of large hospitals to application in hospitals at all levels including grassroots medical institutions, and from application in a few fields to full-scenario application. The company is fully committed to building high-quality products, having developed more than 500 products with performance surpassing domestic and foreign advanced levels, covering infectious disease prevention and control, cancer prevention, maternal and child health, blood screening, sudden epidemic prevention and control, and chronic disease management. It can provide more than 2,200 types of testing services, forming a full industry chain systematic solution integrating reagents, instruments, sequencing services, third-party medical laboratory services, and molecular laboratory co-construction, with products exported to more than 160 countries and regions worldwide. In epidemic prevention and control work, Sansure's COVID-19 nucleic acid detection products have served more than 160 countries and regions worldwide, and the "Sansure Solution" for COVID-19 has become a leading nucleic acid detection solution in Europe, the Middle East, Southeast Asia, and other regions. In numerous public health events, disaster relief efforts, and livelihood projects at home and abroad, Sansure Biotech has actively fulfilled its social responsibility, cumulatively donating nearly 300 million RMB in cash and materials. Making genetic technology accessible to benefit public health. The company will always adhere to the dual-drive of "innovation + service," develop more affordable and user-friendly genetic technologies, products, and services for the public, output the global beneficial "Sansure Solution," assist China in seizing the global high ground of genetic technology and building a community of shared health for mankind, and promote genetic technology to become the backbone of serving human health.